Solid Tumors, Metastasis & Therapy Resistance

Hematopoietic Stem Cells and Leukemia

Stem Cells and Tumor Microenvironment

HI-STEM Group Leaders

previous arrow
next arrow

Prof. Dr. Christof Hettich

Prof Dr. Hettich is a lawyer and partner at RITTERSHAUS Rechtsanwälte in Mannheim, Germany and is specializing the fields of Mergers & Acquisitions, the structuring and restructuring of companies as well as general corporate law. He is also a co-founder and managing director of dievini Hopp BioTech holding GmbH & Co. KG. For many years he has been on boards of private and publicly traded companies in different industry sectors. Dr. Hettich is currently also the Chief Executive Officer of SRH Holding as well as an honorary professor at the Hochschule Heidelberg. He was for many years also an assistant lecturer at the University of Heidelberg (LL.M. coporate restructuring). He studied law and political science at the Universities of Freiburg, Würzburg and Mannheim, Germany and received his Ph.D. from the University of Würzburg, Germany.

Dr. Friedrich von Bohlen und Halbach

Dr. Friedrich von Bohlen und Halbach is managing director of the dievini Hopp BioTech Holding GmbH & Co. KG. dievini manages the biotechnology interests in companies owned by the SAP co-founder Dietmar Hopp and his family. He worked for the Fresenius AG, FAG Kugelfischer and the WASAG Chemie AG. In 1997 he founded the LION Bioscience AG (ow Sygnis Pharma AG), which he managed for six years as CEO. Since 2004 he is their chairman. In addition, he is actively participating in several boards of other biotechnology and biopharmaceutics companies.

Michael Baumann

Prof. Dr. Michael Baumann

Since November 2016, Prof. Dr. Michael Baumann is chairman and scientific member of the board of directors of the German Cancer Research Center.

Prof. Baumann is a specialist in radiooncology. Before taking his position at the DKFZ, he was Chair of the Department of Radiation Oncology at the University Hospital Carl Gustav Carus, director at the Institute for Radiooncology at the Helmholtz Center Dresden-Rossendorf, as well as director of the OncoRay Center. Furthermore, he was the founding director of the University Cancer Center Dresden and spokesperson of the DKTK and NCT partner site Dresden. His research focuses on translational-orientated experimental radiotherapy and radiobiology, as well as the treatment of lung and head and neck cancer.

More information:


Ursula Weyrich ((c): DKFZ)

Ursula Weyrich

Since January 2020, Ursula Weyrich acts as Administrative Director of DKFZ. Before joining the DKFZ, she held executive position at the German Center for Neurodegenerative Diseases, the GSI Helmholtz Centre for Heavy Ion Research and the Facility for Antiproton and Ion Research in Europe (FAIR) GmbH in Darmstadt and at the German Federal Ministry for Education and Research (BMBF).

More information: